Pioneer in phage-based diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations
Menu
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations

Company

Loading...
global unmet need for rapid molecular diagnostic for human TB

Targeting global unmet need for rapid molecular diagnostic for human TB

January 19, 2023
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis (TB) and will be suspending its commercial Johne’s Testing Service.
global unmet need for rapid molecular diagnostic for human TB

Targeting global unmet need for rapid molecular diagnostic for human TB

January 19, 2023
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis...
Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

October 17, 2022
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic with potential to revolutionise management of TB.
Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

October 17, 2022
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic...

Innovation is a key differentiator, PBD Biotech CEO to say at Invest Midlands

January 17, 2022
Innovation directed at an unmet market need can stimulate economic development if the value creation is kept within the local economy. The recent pandemic has shown the huge value of diagnostics and tuberculosis (TB), for which there are currently few...

Innovation is a key differentiator, PBD Biotech CEO to say at Invest Midlands

January 17, 2022
Innovation directed at an unmet market need can stimulate economic development if the value creation is kept within the local...
Jane Theaker, CEO, PBD Biotech (c) Chelsea Shoesmith Photography - square

Jane Theaker appointed as new CEO as PBD Biotech gears up for next phase of development

December 10, 2021
PBD Biotech, developers of a phage-based diagnostic for tuberculosis, is moving to the next stage of its development. It is appointing Jane Theaker, of precision medicine company Kinomica, as the new CEO and bringing Commercial Director, Jonnie Yewdall, into a...
Jane Theaker, CEO, PBD Biotech (c) Chelsea Shoesmith Photography - square

Jane Theaker appointed as new CEO as PBD Biotech gears up for next phase of development

December 10, 2021
PBD Biotech, developers of a phage-based diagnostic for tuberculosis, is moving to the next stage of its development. It is...
Berwyn Clarke

PBD Biotech CEO announces his retirement

April 18, 2019
After growing PBD Biotech from start-up to international player in just three years, Dr Berwyn Clarke has decided to retire as CEO to make time for other business interests. He will remain on the diagnostics company’s Board of Directors.
Berwyn Clarke

PBD Biotech CEO announces his retirement

April 18, 2019
After growing PBD Biotech from start-up to international player in just three years, Dr Berwyn Clarke has decided to retire...
Bacteria Actiphage assay workflow biomarker for TB prevention

PBD Biotech secures grant of key patent for new bacterial diagnostic technology

October 25, 2018
PBD Biotech Limited is pleased to announce that its key technology patent has been granted by the European Patent Office.
Bacteria Actiphage assay workflow biomarker for TB prevention

PBD Biotech secures grant of key patent for new bacterial diagnostic technology

October 25, 2018
PBD Biotech Limited is pleased to announce that its key technology patent has been granted by the European Patent Office.
Dr Berwyn Clarke at REAP

‘Angel investors bring more than money’ – Interview with PBD Biotech CEO

August 7, 2018
Following PBD Biotech’s successful seed funding round, CEO Dr Berwyn Clarke spoke to Growth Business, the leading media portal for entrepreneurs, about the start-up’s strategic approach to securing the right investment for phage-based technology.
Dr Berwyn Clarke at REAP

‘Angel investors bring more than money’ – Interview with PBD Biotech CEO

August 7, 2018
Following PBD Biotech’s successful seed funding round, CEO Dr Berwyn Clarke spoke to Growth Business, the leading media portal for...

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

BIVDA member 2023
Twitter Youtube Linkedin

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house